LMR Partners’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

LMR Partners’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$42.8M	Buy	270,400 +220,400	+441%	+$29.8M	0.16%	140
2026 Q1	$6.39M	Buy	+50,000	New	+$6.24M	0.01%	564
2025 Q1	–	Sell	-175,000	Closed	-$15.8M	–	1666
2024 Q4	$15.8M	Buy	175,000 +125,000	+250%	+$12.1M	0.13%	155
2024 Q3	$4.94M	Sell	50,000 -149,300	-75%	-$14.7M	0.04%	369
2024 Q2	$18.5M	Buy	+199,300	New	+$17.9M	0.16%	124
2024 Q1	–	Sell	-200,200	Closed	-$17.9M	–	1332
2023 Q4	$17.9M	Sell	200,200 -180,000	-47%	-$13.4M	0.2%	118
2023 Q3	$27.8M	Hold	380,200	–	–	0.31%	68
2023 Q2	$31.6M	Buy	+380,200	New	+$31.8M	0.35%	61

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

LMR Partners's XBI Position: Q2 2026 in Review

LMR Partners increased its State Street SPDR S&P Biotech ETF (XBI) stake by 536% in Q2 2026, buying an estimated $15M and bringing the position to 131,711 shares worth $20.8M. The position accounts for 0.08% of the portfolio, ranked #231.

LMR Partners first reported a position in XBI in Q2 2021 and has held it in 15 quarters since. The position peaked at $69.4M in Q2 2022. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

LMR Partners held 131,711 shares of State Street SPDR S&P Biotech ETF worth $20.8M as of Q2 2026.
LMR Partners bought 111,011 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $15M.
State Street SPDR S&P Biotech ETF made up 0.08% of LMR Partners's portfolio in Q2 2026, its #231 holding.
LMR Partners first reported a position in State Street SPDR S&P Biotech ETF in Q2 2021 and has held it in 15 quarters since.
LMR Partners's State Street SPDR S&P Biotech ETF position peaked at $69.4M in Q2 2022.
933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.